Abstract
Multidrug therapy (MDT) recommended by the WHO, which combines rifampicin, dapsone, and clofazimine, has great efficacy in leprosy treatment, as the relapse risk is very low. However, other antibiotics and other therapeutic schemes are studied to protect against the risk of development of resistance against current drugs as well as to try to decrease the length of treatment, which varies according to the clinical forms of illness from 6 to 24 months. Moreover, leprosy reactions, which can occur during or after specific treatment, should be well controlled, because of the importance of neurological complications. The importance of early treatment of leprosy should be underlined. It must be prescribed in the initial, purely dermatological stages to avoid the almost inevitable evolution towards neurological complications.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Grosset JH (1995) Traitement anti-bactérien dans la lèpre. In: Sansarricq H (ed) La lèpre: Ellipses, pp 226–244
Bobin PL (2007) Encycl. Med. Chir. (Elsevier Paris) Maladies infectieuses 8-038-F-10
Grosset JH, Guelpa-Lauras CC, Bobin P, Brucker G, Cartel JL, Constant-Desportes M et coll (1989) Study of 39 documented relapses of multibacillary leprosy after treatment with rifampin. Int J Lepr 57:607–614
Honoré N, Perani E, Telenti A, Grosset J, Cole ST (1993) A simple and rapid technique for the detecio inizialetion of rifampin resistance in M. leprae. Int J Lepr 61:600–604
WHO Study Group (1994) Chemotherapy of leprosy Geneva, World Health Organization 1994 WHO Technical Report Series no 847
Daumerie D (1996) Stratégie d’élimination de la lèpre en tant que problème de santé publique. Acta Leprol 10:3–10
McDougall AC, Yuasa Y (2002) A new atlas of leprosy. Sasakawa Memorial Health Foundation, Tokyo
de Carsalade GY et al (1997) Daily multidrug therapy for leprosy: results of a fourteen-year experience. Int J Lepr 65:37–44
Grosset JH, Ji B, Guelpa-Lauras CC, Perani EG (1990) Clinical trial of pefloxacin and ofloxacin in the treatment of lepromatous leprosy. Int J Lepr 58:281–295
Ji B, Perani EG, Petinon C, Grosset JH (1996) Bactericidal activities of combination of news drugs against M. leprae in nude mice. Antimicrob Agents Chemother 40:393–399
Milan J, Bobin P (1995) Traitement des réactions lépreuses. In: Sansarricq H (ed) La lèpre: Ellipses, pp 250–257
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag Italia
About this chapter
Cite this chapter
Bobin, P. (2012). Treatment and Prophylaxis. In: Nunzi, E., Massone, C. (eds) Leprosy. Springer, Milano. https://doi.org/10.1007/978-88-470-2376-5_28
Download citation
DOI: https://doi.org/10.1007/978-88-470-2376-5_28
Published:
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-2375-8
Online ISBN: 978-88-470-2376-5
eBook Packages: MedicineMedicine (R0)